003017.SZ
大洋生物
SZSE · Basic Materials · C 制造业 · CN
CNY 22.48
+0.27%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 1.0B | 910.0M | 919.5M | 1.1B |
| Cost of Revenue | 827.6M | 806.1M | 732.1M | 753.2M | 911.9M |
| Gross Profit | 247.0M | 239.4M | 177.9M | 166.3M | 146.3M |
| Operating Expenses | |||||
| R&D Expense | 43.9M | 43.8M | 28.8M | 39.2M | 34.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 77.5M | 75.2M | 69.6M | 67.1M | 58.7M |
| Selling & Marketing Expense | 11.2M | 11.6M | 9.8M | 9.8M | 8.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 139.6M | 135.8M | 112.6M | 121.3M | 110.8M |
| Cost and Expenses | 967.2M | 941.9M | 844.7M | 874.5M | 1.0B |
| Operating Income (EBIT) | 112.1M | 110.2M | 75.4M | 56.3M | 59.2M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 110.7M | 106.9M | 71.6M | 47.0M | 57.5M |
| Income Tax Expense | 9.0M | 6.8M | 7.9M | (3.0M) | (23.3M) |
| Bottom Line | |||||
| Net Income | 101.4M | 99.9M | 63.7M | 50.0M | 80.7M |
| Earnings from Cont. Ops | 101.6M | 100.1M | 63.7M | 50.0M | 80.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 101.4M | 99.9M | 63.7M | 50.0M | 80.7M |
| Per Share | |||||
| Basic EPS | CN¥1.25 | CN¥1.23 | CN¥0.78 | CN¥0.62 | CN¥1.39 |
| Diluted EPS | CN¥1.25 | CN¥1.21 | CN¥0.78 | CN¥0.62 | CN¥1.39 |
| Revenue Per Share | CN¥13.23 | CN¥12.83 | CN¥11.17 | CN¥11.39 | CN¥18.18 |
| Shares | |||||
| Basic Shares Outstanding | 81.2M | 81.5M | 81.5M | 80.7M | 58.2M |
| Diluted Shares Outstanding | 81.2M | 81.5M | 81.5M | 80.7M | 58.2M |
| Profitability Metrics | |||||
| EBITDA | — | 182.2M | 143.4M | 125.2M | 118.6M |
| D&A | — | 72.0M | 68.0M | 68.9M | 59.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026